H. Lundbeck A/S

🇩🇰Denmark

Country: 🇩🇰Denmark

Ownership: Public, Subsidiary

Established: 2000-01-01

Employees: 5.6K

Market Cap: -

Website: http://www.lundbeck.com

Clinical Trials

Study With Vortioxetine on Emotional Functioning in Patients With Depression

Phase 4

Completed

Conditions: Major Depressive Disorder

Interventions: Drug: Vortioxetine

First Posted Date: 2019-02-08

Last Posted Date: 2020-03-24

Lead Sponsor: H. Lundbeck A/S

Target Recruit Count: 150

Registration Number: NCT03835715

Locations: 🇫🇷
Cabinet Psyche (FR0012), Douai, France
🇱🇹
JSC Romuvos Klinika (LT0002), Kaunas, Lithuania
🇪🇸
University of Oviedo (ES0011), Oviedo, Spain

and more 20 locations

A Positron Emission Tomography (PET) Study to Examine the Brain Binding Properties of a Novel Radioactive Compound [11C]-PXT012253 in Healthy Subjects

Early Phase 1

Completed

Conditions: Parkinson Disease

Interventions: Drug: [11C]PXT012253

First Posted Date: 2019-02-01

Last Posted Date: 2020-02-05

Lead Sponsor: H. Lundbeck A/S

Target Recruit Count: 7

Registration Number: NCT03826134

Locations: 🇸🇪
Karolinska Institute, Dept. of Clinical Neuroscience, Stockholm, Sweden

Study With Lu AF20513 in Patients With Mild Alzheimer's Disease (AD) or Mild Cognitive Impairment (MCI) Due to AD

Phase 1

Terminated

Conditions: Alzheimer Disease

Interventions: Drug: Lu AF20513
Biological: booster vaccine

First Posted Date: 2019-01-28

Last Posted Date: 2020-02-21

Lead Sponsor: H. Lundbeck A/S

Target Recruit Count: 3

Registration Number: NCT03819699

Locations: 🇸🇪
Karolinska University Hospital, Huddinge (SE001), Stockholm, Sweden
🇫🇮
Clinical Research Services Turku Oy (FI001), Turku, Finland
🇫🇮
University of Eastern Finland, Brain Research Unit (FI002), Kuopio, Finland

Study With Lu AF11167 for the Treatment of Negative Symptoms in Patients With Schizophrenia

Phase 2

Terminated

Conditions: Schizophrenia

Interventions: Drug: Lu AF11167 (1-2 mg/day)
Drug: Lu AF11167 (3-4 mg/day)
Drug: Placebo

First Posted Date: 2019-01-04

Last Posted Date: 2020-09-23

Lead Sponsor: H. Lundbeck A/S

Target Recruit Count: 168

Registration Number: NCT03793712

Locations: 🇱🇻
Sigulda Hospital Outpatient Clinic (LV0006), Sigulda, Latvia
🇵🇱
Med-Ars (Pl0010), Bydgoszcz, Poland
🇵🇱
Centrum Zdrowia Psychicznego Biomed - Jan Latala (PL0006), Kielce, Poland

and more 50 locations

Vortioxetine Intravenous Infusion at Initiation of Oral Treatment With Vortioxetine in Patients With Depression

Phase 2

Completed

Conditions: Major Depressive Disorder

Interventions: Drug: Placebo infusion
Drug: Vortioxetine infusion 25 mg
Drug: Vortioxetine tablets 10 mg/day
Drug: Placebo tablets

First Posted Date: 2018-12-06

Last Posted Date: 2019-08-29

Lead Sponsor: H. Lundbeck A/S

Target Recruit Count: 80

Registration Number: NCT03766867

Locations: 🇧🇬
MHAT "Dr. Hristo Stambolski", EOOD (BG1001), Kazanlak, Bulgaria
🇧🇬
State Psychiatric Hospital "Sv. Ivan Rilski" (BG1009), Novi Iskar, Bulgaria
🇧🇬
Mental Health Centre 'Prof. Dr. Ivan Temkov', EOOD (BG1004), Burgas, Bulgaria

and more 10 locations

Study With Lu AF35700 in Healthy Men and Women in Fasting and Fed State

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Lu AF35700
Drug: Lu AF35700 iv

First Posted Date: 2018-09-13

Last Posted Date: 2019-11-01

Lead Sponsor: H. Lundbeck A/S

Target Recruit Count: 10

Registration Number: NCT03670082

Locations: 🇬🇧
Covance, Leeds, United Kingdom

Study in Healthy Subjects to Compare Two Tablet Formulations of Memantine (Ebixa®) in Fasted and Fed Conditions

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Lactose-free memantine
Drug: Memantine

First Posted Date: 2018-09-13

Last Posted Date: 2024-02-29

Lead Sponsor: H. Lundbeck A/S

Target Recruit Count: 64

Registration Number: NCT03670095

Locations: 🇨🇳
Shuguang Hospital, Shanghai TCM University, Shanghai, China

A Study to Evaluate the Long-term Safety and Tolerability of Lu AF20513 and the Antibody Response in Patients With Alzheimer's Disease (AD)

Phase 1

Terminated

Conditions: Alzheimer's Disease

Interventions: Drug: Lu AF20513

First Posted Date: 2018-09-12

Last Posted Date: 2019-11-21

Lead Sponsor: H. Lundbeck A/S

Target Recruit Count: 18

Registration Number: NCT03668405

Locations: 🇫🇮
FI001, Turku, Finland
🇸🇪
SE003, Mölndal, Sweden
🇸🇪
SE001, Stockholm, Sweden

and more 1 locations

Lu AF82422 in Healthy Non-Japanese and Japanese Subjects and in Patients With Parkinson's Disease

Phase 1

Completed

Conditions: Healthy
Parkinson Disease

Interventions: Drug: Lu AF82422
Drug: Placebo

First Posted Date: 2018-08-02

Last Posted Date: 2021-10-12

Lead Sponsor: H. Lundbeck A/S

Target Recruit Count: 74

Registration Number: NCT03611569

Locations: 🇺🇸
California Clinical Trials Medical Group (CCTMG), Glendale, California, United States
🇺🇸
Reserach Center of America, Hollywood, Florida, United States
🇺🇸
PPD, Orlando, Florida, United States

and more 1 locations

Single Dose of Lu AF28996 to Healthy Young Men

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Lu AF28996 solution
Drug: Lu AF28996 capsule

First Posted Date: 2018-06-21

Last Posted Date: 2019-09-26

Lead Sponsor: H. Lundbeck A/S

Target Recruit Count: 39

Registration Number: NCT03565094

Locations: 🇳🇱
QPS Netherlands BV, Groningen, Netherlands

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy